The FDA has approved a new test that may help determine which breast cancer patients will benefit from certain drugs.
The test is called "Spot-Light" and it can determine how many "Her-2" genes there are in a tumor. Her-2 genes manage the growth of cancer cells. Doctors know that when a patient has too many of them cancer grows and divides more quickly. The new test uses chemicals to make the Her-2 genes change color allowing doctors to see whether a patient needs special treatment for that.
Spot-Light is manufactured by Invitrogen Corp. of Carlsbad, California.